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ABSTRACT 
 
Objective 
Changes in the white matter of dementia with Lewy bodies (DLB) and Alzheimer’s disease (AD) have 
been reported using diffusion weighted MRI, though few longitudinal studies have been done.  
Methods 
We performed diffusion weighted MRI twice, a year apart on 23 AD, 14 DLB, and 32 healthy control 
subjects. Mean diffusivity (MD) and fractional anistropy (FA) were calculated.  
Results 
In AD, there were widespread regions where the longitudinal MD increase was greater than in 
controls, and small areas in the parietal and temporal lobes where it was greater in AD than DLB.  In 
AD, decrease in brain volume correlated with increased MD. There were no significant differences in 
progression between DLB and controls. 
Conclusions 
In AD the white matter continues to degenerate during the disease process, whereas in DLB, 
changes in the white matter structure are a relatively early feature. Different mechanisms are likely 
to underpin changes in diffusivity. 
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OBJECTIVE 
Dementia with Lewy bodies (DLB) is a common form of neurodegenerative dementia in older 
people, second to Alzheimer’s disease (AD). Studies of DLB have found relatively less overall brain 
atrophy than AD, particularly in the temporal lobes.[1] A number of studies have investigated the 
structural integrity of the white matter in DLB using MR diffusion tensor imaging (DTI) and have 
found mixed results, but generally, DLB subjects have DTI changes in parieto-occipital regions, whilst 
AD changes are more widespread, and have been reported to particularly involve the medial 
temporal lobe and limbic pathways.[1, 2]  
In a previous study, we found widespread reductions of fractional anisotropy (FA) in AD, with DLB 
changes more restricted to parieto-occipital regions, along with generally increased mean diffusivity 
(MD) in both groups.[3] In this study, we report the longitudinal change in MD and FA measured 
over 1 year in these subjects. 
 
METHODS 
Subjects 
Seventy-one individuals aged over 60 (36 subjects with probable AD[4] and 35 with probable DLB[5]) 
were recruited from a community-dwelling population of patients referred to local old age 
psychiatry, geriatric medicine, or neurology services. Thirty-five control subjects were recruited from 
relatives and friends of subjects with dementia or volunteered via local advertisements. All subjects 
underwent clinical and neuropsychological evaluations with diagnostic procedures as previously 
described.[3] MR scanning was done on all subjects at baseline and was repeated after 1 year on 
those subjects who consented for repeat scanning. The research was approved by the local ethics 
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committee. All subjects or, where appropriate, their nearest relative, provided written informed 
consent. 
Of the 36 AD subjects, 23 were included after 11 were unable to participate in the follow-up 
assessment, one AD was excluded due to excessive motion on the repeat DT images, and DTI data 
were not available on another. Of the 35 DLB subjects, 14 were included after 12 declined to 
participate due to ill health, and 9 subjects had died. Of the 35 HC subjects, 32 were included in the 
present analyses after 2 declined to participate, and DTI data were not available on one control.  
Assessment of global cognitive measures in all subjects (those with AD or DLB and controls) involved 
use of the Cambridge Cognitive Examination (CAMCOG), which incorporates the Mini-Mental State 
Examination (MMSE).[6] Verbal episodic memory and visual episodic memory were assessed with 
the Hopkins Verbal Learning Test (HVLT) and Brief Visual Memory Task–Revised (BVMT), 
respectively, and a composite z-score of episodic memory (verbal and visual) relative to control 
group performance was derived to incorporate all aspects of the memory task, as described 
previously.[3] 
Verbal fluency was assessed with the Delis Kaplan letter fluency task (FAS). Motor parkinsonism was 
assessed with the Unified Parkinson's Disease Rating Scale Part III (UPDRS-III).[7] 
 
Imaging 
Subjects underwent MRI scanning on a 3T MRI system (Intera Achieva scanner, Philips Medical 
Systems, Eindhoven, Netherlands) with an 8-channel receiver head coil within 2 months of the 
baseline cognitive study assessment, and at 1 year after the initial scan. 
DTI images were acquired using a Pulsed Gradient Spin Echo (PGSE) sequence and multi-slice single 
shot EPI readout, with 24 slices. TE=71 ms and TR=2524 ms with 2 mm in-plane resolution, 6 mm 
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slice thickness and matrix size of 128 x 128.  Diffusion weighting was in 16 directions with a b value 
of 1000 s.mm-2 and a single measurement at b=0 s.mm-2. 
A T1 weighted volumetric sequence (3D MPRAGE, sagittal acquisition, 1 mm isotropic resolution and 
matrix size of 240  x 240  x 180; TR=9.6ms; TE=4.6ms; flip angle=8°; SENSE factor=2) was also 
acquired.  Additionally, we acquired quantitative images using a fast quantitative T1 measurement 
based on a custom inversion recovery prepared EPI sequence (axial slices, 2 mm isotropic resolution, 
matrix 128 × 128 × 72, TR = 15 s, TE = 24 ms, inversion time TIR = 0.25–2.5 s in 12 uniform steps); and 
a fast quantitative multi-echo T2 measurement based on a Gradient and Spin Echo Imaging 
sequence (2 mm isotropic resolution, matrix 128 × 128 × 72, TR = 4.7 s, 8 spin echoes at 20 ms 
spacing, EPI factor 5). 
 
Image processing 
Data were processed with the FSL toolbox (http://fsl.fmrib.ox.ac.uk/fsl/fslwiki/). The DTI images 
were processed to correct for subject motion and eddy current distortion, and fractional anisotropy 
(FA) and mean diffusivity (MD) calculated. The baseline and 1 year FA images were spatially 
registered together, by calculating the transform from base to 1 year, and vice versa, and resampling 
both images to the space halfway between them. The average of the baseline  and 1 year FA maps 
was then calculated, along with the difference of the two MD and FA maps. We then used the TBSS 
package in FSL to align the average FA maps for each subject to the standard template, and to create 
a mean FA skeleton representing the centres of all tracts common to the cohort. Each subject's 
difference FA and MD data were then projected onto the mean FA skeleton. Voxelwise statistics on 
the skeleton were then performed on the difference images to look for longitudinal increases or 
decreases in FA and MD between groups. This was done as an ANOVA, without covariates, and also 
with the addition of age, sex, and WMH score to the model. We used the TFCE (threshold-free 
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cluster enhancement)[8] to find regions of significant difference between groups correcting for 
multiple comparisons. We also calculated the mean (and SD) of change in FA and MD within the 
entire skeleton for each group. Reported clusters are all p<0.05 corrected for multiple comparisons. 
In addition, we used the FSL SIENA package to determine longitudinal brain atrophy from the 3D T1 
weighted images, as described in our previous publication.[9] 
In order to visualise white matter hyperintensities, an image with contrast resembling a FLAIR (fluid 
attenuated inversion recovery) sequence was calculated from the quantitative T1 and T2 maps [10] 
and the standard image contrast for inversion recovery. [11] The resulting images (see 
supplementary figure e1 for examples) were reviewed by two experienced raters (RB, SJC) who rated 
the white matter hyperintensities according to the Fazekas scale. [12] We took the deep WMH score 
as representative of vascular disease and included it in the analysis of the DTI data. 
STATISTICS 
We used SPSS (version 22, IBM, New York, USA) for analysis of non imaging data. Group comparisons 
were performed with ANOVA or Chi square. Comparison of mean FA and MD controlling for 
covariates was done with the general linear model, with fixed factors of group and sex, and 
covariates of age and deep WMH rating. Correlations performed with Pearson correlation.  
 
RESULTS 
Table 1 shows the subject demographics of the study participants with repeat DTI data. AD and DLB 
were well matched for overall cognitive impairment, though as expected,  AD subjects performed 
worst on baseline episodic memory.  The DLB subjects showed significant progression of motor 
features as assessed by increased UPDRS (p=0.045).  There were no significant differences between 
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groups in WMH rating score. WMH score was significantly correlated (p<0.001) with both mean FA 
and MD in the whole white matter at baseline, controlling for group and age. 
Since a number of subjects had dropped out since our original baseline DTI study [3], we repeated 
analysis of the baseline FA and MD, but including only the subjects in the present report. The results 
from subjects with followup data were similar to those in the whole group, with FA decreased, and 
MD increased, in both AD and DLB (suppl. Figures e2 & e3). 
We found regions throughout the white matter where MD increased longitudinally in AD relative to 
controls [figure 1]. There were also small regions in the left parietal and temporal lobe where the 
MD increases in AD were greater than DLB. No regions of significant change in MD were found in 
DLB or controls, or in FA in any group. Addition of covariates of age, sex and WMH rating did not 
qualitatively change these results. The mean increase in MD in the whole skeleton was significantly 
different between groups, (control 0.0044 SD 0.009 x10−3 mm2 s-1 ; AD 0.0139 SD 0.016 x10−3 mm2 s-1 
; DLB 0.0056 SD 0.019 x10−3 mm2 s-1) F2,66=3.2, p=0.047, with post hoc AD > control (Tukey p=0.045). 
The group difference was still significant after including age, sex and WMH in the model (F2,63=3.3, 
p=0.038). Neither age, sex, nor baseline WMH rating significantly predicted change in MD (p>0.1). 
Overall change in mean FA in the whole skeleton was not significantly different (F2,66=1.2, 
p=0.3)between groups (Control -0.0005 SD 0.005; AD -0.0026 SD 0.0049; DLB -0.0009 SD 0.00589). 
Change in mean FA was still not significant between groups (p=0.087) after the addition of age, sex 
and WMH rating to the model .  
We investigated the correlation between change in whole skeleton FA & MD and the percentage 
change in brain volume over the same period [9]. There was a significant correlation between brain 
atrophy and MD change both in the whole group (r=0.49; p<0.001 ) and the AD (r=0.536; p=0.010) 
and control (r=0.678; p<0.001) but not DLB (r=0.07; p=0.8) groups. Change in FA did not significantly 
correlate with longitudinal brain atrophy in the whole group (r=0.23; p=0.058), but was significant in 
the control (r=0.39;p=0.026) but not AD (r=0.05;p=0.8) or DLB (r=-0.08; p=0.8). 
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Within each group, we investigated the correlation between change in mean MD and FA, and change 
in cognitive measures (CAMCOG, MMSE, FAS, episodic memory) and UPDRS. Apart from decrease in 
CAMCOG, which correlated with decrease in FA in the AD group (r=0.47,p=0.023) there were no 
significant correlations. 
 
 
CONCLUSIONS 
 
We found increase of mean diffusivity over 1 year in the AD group to be greater than that in the 
control group over a wide range of brain areas. The increase in MD in AD was also greater than that 
in DLB in parietal and temporal regions. However, there was no evidence of longitudinal change in 
MD or FA in DLB relative to controls. This suggests that the widespread pattern of increased MD and 
reduced FA in AD that we saw at baseline is part of an ongoing degenerative process, whilst the 
alterations seen in DLB may have been an early marker of the disease, with less progression. 
However, we had only 1 year of followup, and relatively small alteration in cognitive score over the 
year, so it is possible that further change in MD and FA could occur as both diseases progress. 
Further study to investigate DTI from the earliest disease point would help clarify the disease 
courses. 
We are aware of only a few  studies investigating longitudinal changes in DTI in dementia. One study 
[13] investigated a mixed group of dementia (including 8 AD) and found regional changes in MD 
correlating with declining language function. That study used a VBM approach with smoothed MD 
images, which may have increased the influence of brain atrophy (via partial volume of CSF) on the 
MD values. A separate study used a region of interest approach to look at changes in MD and FA in 
mild cognitive impairment (MCI) and AD compared to controls. They found longitudinal increases in 
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MD in the Alzheimer’s and MCI group in the cingulum. Only the control group showed change in FA. 
However, a study using tractography of the uncinate fasciculus (UNC), the inferior longitudinal 
fasciculus (ILF) and the inferior occipitofrontal fasciculus (IOFF) in AD found only longitudinally 
increased FA in the UNC of AD.[14]In the AD group, we found changes in MD, but not FA. This is in 
keeping with other previous studies [15-17] which have found greater sensitivity of MD to detect 
differences in AD. Possible reasons for this include the relatively large voxel size, since MD is more 
uniform across the brain than FA, and hence less affected by registration errors. Also, whilst loss of 
white matter fibres will invariably increase MD, the effect on FA will depend on the underlying 
arrangement of the fibres. [15, 18] We saw a relationship between change in FA and atrophy in only 
the control group. This may be due to vascular disease being the primary pathology in control 
subjects, and vascular damage to the white matter leading directly to both altered brain volume, and 
also change in diffusion parameters. In the dementia groups, there will be  greater influence of other 
pathologies (eg amyloid) on brain volume through grey matter damage, which may have less direct 
influence on white matter diffusion parameters. In this study we only investigated changes to the 
white matter major tracts. Future work should consider diffusion changes in the cortical and 
subcortical grey matter. 
 We found very limited evidence of association between cognitive decline and change in diffusion 
parameters. This is in keeping with our previous finding in this group that whole brain atrophy rate 
did not correlate with decline in cognitive score [9]. Possible reasons for this include the relatively 
short period (1 year) between assessments, as well as retest variability in cognitive scores. 
Presence of CSF in voxels can have an influence on MD due to the high diffusivity and proton density 
of water, and it is possible that the correlation between MD and atrophy that we see is caused by 
increased CSF in the voxel. However, previous work [19]  found that the TBSS method was relatively 
insensitive to partial volume effects, since the voxels in the white matter skeleton tend to be away 
from the edges of the brain. Cell shrinkage or loss in the WM will contribute to overall brain atrophy, 
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and there is evidence that change in WM in AD is at least partly independent of GM changes, and 
that it is an important part of the AD pathogenesis.[2] The rate of brain atrophy in DLB is lower than 
AD [1] which also suggests that widespread brain degeneration is less marked in DLB, with changes 
to specific neurotransmitter systems (such as cholinergic or dopaminergic) being more profound. 
The relationship between change in brain volume and increased white matter diffusivity in AD would 
also be consistent with white matter changes in AD being largely secondary to grey matter or 
neuronal loss, so reflecting Wallerian degeneration. In contrast, the lack of such an association in 
DLB is consistent with synaptic dysfunction rather than cell loss as a key feature of the disorder, 
possibly caused by presynaptic accumulation of oligimeric alpha-synuclein.[20]  
 
In conclusion we found that whereas at baseline MD was increased in both AD and DLB, there was a 
continued increase in MD over time only in the AD group, with the DLB showing no change in MD. 
This may be a result of early changes in the DLB group, and studies of people at risk of, or in the very 
early stages of DLB may help clarify the timescale of the disease process. 
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Table Captions 
Table 1 Demographic characteristics of the subjects. 
 
FIGURE CAPTIONS 
Figure 1 Group differences in MD. 
Significant voxels (p < 0.05) in the white matter skeleton corrected for multiple comparisons where 
increase in MD in AD > control (red-yellow) and AD > DLB (blue-pink). The white matter skeleton is 
shown in green. Images are presented in radiological convention (left of image is right of brain) 
 
Supplementary figure e-1 Images with FLAIR type contrast calculated from quantitative T1 and T2 
maps. Left show image rated as WMH = 0 and right WMH = 3. 
 
Supplementary figure e-2 Comparison of FA at baseline in the subjects included in the longitudinal 
analysis.  
Showing p < 0.05 (corrected for multiple comparisons with threshold free cluster enhancement) 
where FA in control > AD and control > DLB. There were no regions where FA was significantly 
decreased in controls relative to dementia 
 
Supplementary figure e-3 Comparison of MD at baseline in the subjects included in the longitudinal 
analysis.  
15 
 
Showing p < 0.05 (corrected for multiple comparisons with threshold free cluster enhancement) 
where MD in AD > control and DLB > controls. There were no regions where MD was significantly 
increased in controls relative to dementia . 
 
